Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID-19: Daily Top 10 Papers

Malignant Melanoma

Free Subscription Articles published in J Clin Oncol Retrieve available abstracts of 69 articles: HTML format

Single Articles

July 2021
1. DIAB A, Tykodi SS, Daniels GA, Maio M, et al
   Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma.
   J Clin Oncol. 2021 Jul 13:JCO2100675. doi: 10.1200/JCO.21.00675.
   PubMed     Abstract available
   
   
   June 2021
2. HUPPERT LA, Daud AI
   Pembrolizumab and Ipilimumab as Second-Line Therapy for Advanced Melanoma.
   J Clin Oncol. 2021 Jun 17:JCO2100943. doi: 10.1200/JCO.21.00943.
   PubMed    
   
   
   
3. CHAPMAN PB
   Targeting Tumor-Rejection Antigens in Melanoma With Tumor-Infiltrating Lymphocytes.
   J Clin Oncol. 2021 Jun 4:JCO2101012. doi: 10.1200/JCO.21.01012.
   PubMed    
   
   
   May 2021
4. SARNAIK AA, Hamid O, Khushalani NI, Lewis KD, et al
   Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma.
   J Clin Oncol. 2021 May 12:JCO2100612. doi: 10.1200/JCO.21.00612.
   PubMed     Abstract available
   
   
   
5. OLSON DJ, Eroglu Z, Brockstein B, Poklepovic AS, et al
   Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma.
   J Clin Oncol. 2021 May 4:JCO2100079. doi: 10.1200/JCO.21.00079.
   PubMed     Abstract available
   
   
   February 2021
6. EL SHAROUNI MA, Ahmed T, Varey AHR, Elias SG, et al
   Development and Validation of Nomograms to Predict Local, Regional, and Distant Recurrence in Patients With Thin (T1) Melanomas.
   J Clin Oncol. 2021 Feb 18:JCO2002446. doi: 10.1200/JCO.20.02446.
   PubMed     Abstract available
   
   
   January 2021
7. SHOUSHTARI AN
   Incorporating VEGF Blockade Into a Shifting Treatment Paradigm for Mucosal Melanoma.
   J Clin Oncol. 2021 Jan 25:JCO2003523. doi: 10.1200/JCO.20.03523.
   PubMed    
   
   
   
8. HINDIE E
   Considerations on the Role of Pembrolizumab Adjuvant Therapy in AJCC-8 Stage IIIA Melanoma.
   J Clin Oncol. 2021 Jan 25:JCO2003213. doi: 10.1200/JCO.20.03213.
   PubMed    
   
   
   
9. YAN X, Sheng X, Chi Z, Si L, et al
   Randomized Phase II Study of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Mucosal Melanoma.
   J Clin Oncol. 2021 Jan 14:JCO2000902. doi: 10.1200/JCO.20.00902.
   PubMed     Abstract available
   
   
   
10. PIULATS JM, Espinosa E, de la Cruz Merino L, Varela M, et al
    Nivolumab Plus Ipilimumab for Treatment-Naive Metastatic Uveal Melanoma: An Open-Label, Multicenter, Phase II Trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402).
    J Clin Oncol. 2021 Jan 8:JCO2000550. doi: 10.1200/JCO.20.00550.
    PubMed     Abstract available
    
    
    
11. KHAN S, Carvajal RD
    Dual Immunological Checkpoint Blockade for Uveal Melanoma.
    J Clin Oncol. 2021 Jan 8:JCO2003274. doi: 10.1200/JCO.20.03274.
    PubMed    
    
    
    October 2020
12. PELSTER MS, Gruschkus SK, Bassett R, Gombos DS, et al
    Nivolumab and Ipilimumab in Metastatic Uveal Melanoma: Results From a Single-Arm Phase II Study.
    J Clin Oncol. 2020 Oct 30:JCO2000605. doi: 10.1200/JCO.20.00605.
    PubMed     Abstract available
    
    
    September 2020
13. ROBERT C, Long GV, Brady B, Dutriaux C, et al
    Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma.
    J Clin Oncol. 2020 Sep 30:JCO2000995. doi: 10.1200/JCO.20.00995.
    PubMed     Abstract available
    
    
    
14. EGGERMONT AMM, Blank CU, Mandala M, Long GV, et al
    Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial.
    J Clin Oncol. 2020 Sep 18:JCO2002110. doi: 10.1200/JCO.20.02110.
    PubMed     Abstract available
    
    
    July 2020
15. KARAKOUSIS G, Sondak VK, Zager JS
    Overestimation of Risk for Sentinel Lymph Node Metastasis in a Nomogram for T1 Melanomas.
    J Clin Oncol. 2020 Jul 23:JCO2001686. doi: 10.1200/JCO.20.01686.
    PubMed    
    
    
    
16. OLOFSSON BAGGE R, Kicinski M, Faries MB, Gyorki DE, et al
    Comment on "Factors Affecting Sentinel Node Metastasis in Thin (T1) Cutaneous Melanomas: Development and External Validation of a Predictive Nomogram".
    J Clin Oncol. 2020 Jul 23:JCO2001680. doi: 10.1200/JCO.20.01680.
    PubMed    
    
    
    
17. HINDIE E
    Sentinel Node Biopsy in Patients With Thin Melanoma: A Need to Better Define the Aim.
    J Clin Oncol. 2020 Jul 23:JCO2001199. doi: 10.1200/JCO.20.01199.
    PubMed    
    
    
    June 2020
18. LO SN, Ma J, Scolyer RA, Haydu LE, et al
    Improved Risk Prediction Calculator for Sentinel Node Positivity in Patients With Melanoma: The Melanoma Institute Australia Nomogram.
    J Clin Oncol. 2020 Jun 12:JCO1902362. doi: 10.1200/JCO.19.02362.
    PubMed     Abstract available
    
    
    
19. GARBE C, Keim U, Suciu S, Amaral T, et al
    Prognosis of Patients With Stage III Melanoma According to American Joint Committee on Cancer Version 8: A Reassessment on the Basis of 3 Independent Stage III Melanoma Cohorts.
    J Clin Oncol. 2020 Jun 12:JCO1903034. doi: 10.1200/JCO.19.03034.
    PubMed     Abstract available
    
    
    May 2020
20. FARIES MB
    Improved Tool for Predicting Sentinel Lymph Node Metastases in Melanoma.
    J Clin Oncol. 2020 May 28:JCO2001121. doi: 10.1200/JCO.20.01121.
    PubMed    
    
    
    April 2020
21. TAYLOR MH, Lee CH, Makker V, Rasco D, et al
    Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors.
    J Clin Oncol. 2020;38:1154-1163.
    PubMed     Abstract available
    
    
    March 2020
22. SETH R, Messersmith H, Kaur V, Kirkwood JM, et al
    Systemic Therapy for Melanoma: ASCO Guideline.
    J Clin Oncol. 2020 Mar 31:JCO2000198. doi: 10.1200/JCO.20.00198.
    PubMed     Abstract available
    
    
    
23. MAURICHI A, Miceli R, Eriksson H, Newton-Bishop J, et al
    Factors Affecting Sentinel Node Metastasis in Thin (T1) Cutaneous Melanomas: Development and External Validation of a Predictive Nomogram.
    J Clin Oncol. 2020 Mar 13:JCO1901902. doi: 10.1200/JCO.19.01902.
    PubMed     Abstract available
    
    
    February 2020
24. DAVIES MA
    Is It Safe to Stop Anti-PD-1 Immunotherapy in Patients With Metastatic Melanoma Who Achieve a Complete Response?
    J Clin Oncol. 2020 Feb 25:JCO2000136. doi: 10.1200/JCO.20.00136.
    PubMed    
    
    
    
25. BETOF WARNER A, Palmer JS, Shoushtari AN, Goldman DA, et al
    Long-Term Outcomes and Responses to Retreatment in Patients With Melanoma Treated With PD-1 Blockade.
    J Clin Oncol. 2020 Feb 13:JCO1901464. doi: 10.1200/JCO.19.01464.
    PubMed     Abstract available
    
    
    January 2020
26. HAYDU LE, Lo SN, McQuade JL, Amaria RN, et al
    Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III Melanoma.
    J Clin Oncol. 2020 Jan 28:JCO1901508. doi: 10.1200/JCO.19.01508.
    PubMed     Abstract available
    
    
    December 2019
27. BETOF WARNER A, Postow MA
    Another Victory for Immune Checkpoint Blockade in Melanoma: Adjuvant Ipilimumab Over Interferon.
    J Clin Oncol. 2019 Dec 27:JCO1902988. doi: 10.1200/JCO.19.02988.
    PubMed    
    
    
    
28. TARHINI AA, Lee SJ, Hodi FS, Rao UNM, et al
    Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609.
    J Clin Oncol. 2019 Dec 27:JCO1901381. doi: 10.1200/JCO.19.01381.
    PubMed     Abstract available
    
    
    October 2019
29. MENZER C, Menzies AM, Carlino MS, Reijers I, et al
    Targeted Therapy in Advanced Melanoma With Rare BRAF Mutations.
    J Clin Oncol. 2019 Oct 3:JCO1900489. doi: 10.1200/JCO.19.00489.
    PubMed     Abstract available
    
    
    September 2019
30. LEITER U, Stadler R, Mauch C, Hohenberger W, et al
    Final Analysis of DeCOG-SLT Trial: No Survival Benefit for Complete Lymph Node Dissection in Patients With Melanoma With Positive Sentinel Node.
    J Clin Oncol. 2019 Sep 26:JCO1802306. doi: 10.1200/JCO.18.02306.
    PubMed     Abstract available
    
    
    
31. HONG AM, Fogarty GB, Dolven-Jacobsen K, Burmeister BH, et al
    Adjuvant Whole-Brain Radiation Therapy Compared With Observation After Local Treatment of Melanoma Brain Metastases: A Multicenter, Randomized Phase III Trial.
    J Clin Oncol. 2019 Sep 25:JCO1901414. doi: 10.1200/JCO.19.01414.
    PubMed     Abstract available
    
    
    
32. REGAN MM, Werner L, Rao S, Gupte-Singh K, et al
    Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition-A Pooled Analysis of Patients With Advanced Melanoma.
    J Clin Oncol. 2019 Sep 9:JCO1900345. doi: 10.1200/JCO.19.00345.
    PubMed     Abstract available
    
    
    August 2019
33. SHENG X, Yan X, Chi Z, Si L, et al
    Axitinib in Combination With Toripalimab, a Humanized Immunoglobulin G4 Monoclonal Antibody Against Programmed Cell Death-1, in Patients With Metastatic Mucosal Melanoma: An Open-Label Phase IB Trial.
    J Clin Oncol. 2019 Aug 12:JCO1900210. doi: 10.1200/JCO.19.00210.
    PubMed     Abstract available
    
    
    May 2019
34. LONG GV, Dummer R, Schadendorf D, Santinami M, et al
    Reply to E. Hindie and K.R. Hess.
    J Clin Oncol. 2019;37:1356-1358.
    PubMed    
    
    
    April 2019
35. KLUGER HM, Margolin KA, Davies MA, Long GV, et al
    Reply to A. Shinde et al.
    J Clin Oncol. 2019;37:1031-1032.
    PubMed    
    
    
    
36. BAE JM, Chung KY, Yun SJ, Kim H, et al
    Markedly Reduced Risk of Internal Malignancies in Patients With Vitiligo: A Nationwide Population-Based Cohort Study.
    J Clin Oncol. 2019;37:903-911.
    PubMed     Abstract available
    
    
    
37. HESS KR
    Beneficial Effect of Adjuvant Dabrafenib Plus Trametinib on Recurrence-Free Survival in Patients With Resected BRAF(V600)-Mutant Stage III Melanoma Seems to be Short-Lived.
    J Clin Oncol. 2019 Apr 2:JCO1801768. doi: 10.1200/JCO.18.01768.
    PubMed    
    
    
    
38. HINDIE E
    What Is the Role of Dabrafenib Plus Trametinib Adjuvant Therapy in Stage IIIA Melanoma?
    J Clin Oncol. 2019 Apr 2:JCO1802075. doi: 10.1200/JCO.18.02075.
    PubMed    
    
    
    February 2019
39. LEBBE C, Meyer N, Mortier L, Marquez-Rodas I, et al
    Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial.
    J Clin Oncol. 2019 Feb 27:JCO1801998. doi: 10.1200/JCO.18.01998.
    PubMed     Abstract available
    
    
    
40. SHINDE A, Li R, Amini A, Glaser S, et al
    Can Immunotherapy Replace Radiotherapy in Melanoma Brain Metastases?
    J Clin Oncol. 2019 Feb 26:JCO1801982. doi: 10.1200/JCO.18.01982.
    PubMed    
    
    
    November 2018
41. KLUGER HM, Chiang V, Mahajan A, Zito CR, et al
    Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial.
    J Clin Oncol. 2018 Nov 8:JCO1800204. doi: 10.1200/JCO.18.00204.
    PubMed     Abstract available
    
    
    October 2018
42. DAVAR D, Wang H, Chauvin JM, Pagliano O, et al
    Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma.
    J Clin Oncol. 2018 Oct 25:JCO1800632. doi: 10.1200/JCO.18.00632.
    PubMed     Abstract available
    
    
    
43. HAUSCHILD A, Dummer R, Schadendorf D, Santinami M, et al
    Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600-Mutant Stage III Melanoma.
    J Clin Oncol. 2018 Oct 22:JCO1801219. doi: 10.1200/JCO.18.01219.
    PubMed     Abstract available
    
    
    March 2018
44. CARVAJAL RD, Piperno-Neumann S, Kapiteijn E, Chapman PB, et al
    Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT).
    J Clin Oncol. 2018 Mar 12:JCO2017741090. doi: 10.1200/JCO.2017.74.1090.
    PubMed     Abstract available
    
    
    February 2018
45. KHUSHALANI NI
    Duration of Anti-Programmed Death-1 Therapy in Advanced Melanoma: How Much of a Good Thing Is Enough?
    J Clin Oncol. 2018 Feb 1:JCO2017768275. doi: 10.1200/JCO.2017.76.8275.
    PubMed     Abstract available
    
    
    January 2018
46. HORIGUCHI M, Uno H, Wei LJ
    Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab as a Result of Adverse Events Lived Significantly Longer Than Patients Who Continued Treatment.
    J Clin Oncol. 2018 Jan 16:JCO2017760983. doi: 10.1200/JCO.2017.76.0983.
    PubMed    
    
    
    December 2017
47. ROBERT C, Ribas A, Hamid O, Daud A, et al
    Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma.
    J Clin Oncol. 2017 Dec 28:JCO2017756270. doi: 10.1200/JCO.2017.75.6270.
    PubMed     Abstract available
    
    
    
48. BUTOW PN, Turner J, Gilchrist J, Sharpe L, et al
    Randomized Trial of ConquerFear: A Novel, Theoretically Based Psychosocial Intervention for Fear of Cancer Recurrence.
    J Clin Oncol. 2017;35:4066-4077.
    PubMed     Abstract available
    
    
    
49. WONG SL, Faries MB, Kennedy EB, Agarwala SS, et al
    Sentinel Lymph Node Biopsy and Management of Regional Lymph Nodes in Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline Update.
    J Clin Oncol. 2017 Dec 12:JCO2017757724. doi: 10.1200/JCO.2017.75.7724.
    PubMed     Abstract available
    
    
    October 2017
50. CARLINO MS, Sandhu S
    Safety and Efficacy Implications of Discontinuing Combination Ipilimumab and Nivolumab in Advanced Melanoma.
    J Clin Oncol. 2017 Oct 19:JCO2017752055. doi: 10.1200/JCO.2017.75.2055.
    PubMed    
    
    
    
51. CALLAHAN MK, Kluger H, Postow MA, Segal NH, et al
    Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study.
    J Clin Oncol. 2017 Oct 17:JCO2017722850. doi: 10.1200/JCO.2017.72.2850.
    PubMed     Abstract available
    
    
    
52. LONG GV, Eroglu Z, Infante J, Patel S, et al
    Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib.
    J Clin Oncol. 2017 Oct 9:JCO2017741025. doi: 10.1200/JCO.2017.74.1025.
    PubMed     Abstract available
    
    
    
53. CHESNEY J, Puzanov I, Collichio F, Singh P, et al
    Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma.
    J Clin Oncol. 2017 Oct 5:JCO2017737379. doi: 10.1200/JCO.2017.73.7379.
    PubMed     Abstract available
    
    
    September 2017
54. SZNOL M, Ferrucci PF, Hogg D, Atkins MB, et al
    Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma.
    J Clin Oncol. 2017 Sep 15:JCO2016721167. doi: 10.1200/JCO.2016.72.1167.
    PubMed     Abstract available
    
    
    August 2017
55. SCHADENDORF D, Wolchok JD, Hodi FS, Chiarion-Sileni V, et al
    Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials.
    J Clin Oncol. 2017 Aug 25:JCO2017732289. doi: 10.1200/JCO.2017.73.2289.
    PubMed     Abstract available
    
    
    July 2017
56. LARKIN J, Minor D, D'Angelo S, Neyns B, et al
    Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial.
    J Clin Oncol. 2017 Jul 3:JCO2016718023. doi: 10.1200/JCO.2016.71.8023.
    PubMed     Abstract available
    
    
    June 2017
57. BURRIS HA, Infante JR, Ansell SM, Nemunaitis JJ, et al
    Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors.
    J Clin Oncol. 2017;35:2028-2036.
    PubMed     Abstract available
    
    
    April 2017
58. HAYDU LE, Scolyer RA, Lo S, Quinn MJ, et al
    Conditional Survival: An Assessment of the Prognosis of Patients at Time Points After Initial Diagnosis and Treatment of Locoregional Melanoma Metastasis.
    J Clin Oncol. 2017 Apr 4:JCO2016719393. doi: 10.1200/JCO.2016.71.9393.
    PubMed     Abstract available
    
    
    February 2017
59. KOHN CG, Zeichner SB, Chen Q, Montero AJ, et al
    Cost-Effectiveness of Immune Checkpoint Inhibition in BRAF Wild-Type Advanced Melanoma.
    J Clin Oncol. 2017 Feb 21:JCO2016696336. doi: 10.1200/JCO.2016.69.6336.
    PubMed     Abstract available
    
    
    January 2017
60. AGARWALA SS, Lee SJ, Yip W, Rao UN, et al
    Phase III Randomized Study of 4 Weeks of High-Dose Interferon-alpha-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Rese
    J Clin Oncol. 2017 Jan 30:JCO2016702951. doi: 10.1200/JCO.2016.70.2951.
    PubMed     Abstract available
    
    
    
61. D'ANGELO SP, Larkin J, Sosman JA, Lebbe C, et al
    Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis.
    J Clin Oncol. 2017;35:226-235.
    PubMed     Abstract available
    
    
    
62. WATTS CG, Cust AE, Menzies SW, Mann GJ, et al
    Cost-Effectiveness of Skin Surveillance Through a Specialized Clinic for Patients at High Risk of Melanoma.
    J Clin Oncol. 2017;35:63-71.
    PubMed     Abstract available
    
    
    December 2016
63. POWELL CA
    Pulmonary Infiltrates in a Patient With Advanced Melanoma.
    J Clin Oncol. 2016 Dec 28:JCO2016699793.
    PubMed     Abstract available
    
    
    
64. DIENG M, Butow PN, Costa DS, Morton RL, et al
    Psychoeducational Intervention to Reduce Fear of Cancer Recurrence in People at High Risk of Developing Another Primary Melanoma: Results of a Randomized Controlled Trial.
    J Clin Oncol. 2016;34:4405-4414.
    PubMed     Abstract available
    
    
    
65. DAUD AI, Wolchok JD, Robert C, Hwu WJ, et al
    Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma.
    J Clin Oncol. 2016;34:4102-4109.
    PubMed     Abstract available
    
    
    November 2016
66. NIJSTEN T
    Sunscreen Use in the Prevention of Melanoma: Common Sense Rules.
    J Clin Oncol. 2016;34:3956-3958.
    PubMed    
    
    
    
67. WEBER JS, Hodi FS, Wolchok JD, Topalian SL, et al
    Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma.
    J Clin Oncol. 2016 Nov 14:JCO2015661389.
    PubMed     Abstract available
    
    
    September 2016
68. GHIASVAND R, Weiderpass E, Green AC, Lund E, et al
    Sunscreen Use and Subsequent Melanoma Risk: A Population-Based Cohort Study.
    J Clin Oncol. 2016 Sep 12. pii: JCO675934.
    PubMed     Abstract available
    
    
    January 2016
69. BULLOCH KJ, Narayan D, Ariyan S, Gould Rothberg BE, et al
    Correlation of body mass index with female survival benefit among a single-institution cohort of cutaneous melanomas >1 mm thick following wide-local excision and sentinel lymph node biopsy.
    J Clin Oncol. 2016;34.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Malignant Melanoma is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: